Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer Disease 2 Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

NCT02079909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T-817MA-H, T-817MA-L, Placebo
Drug
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Industry
Eligibility
55 Years to 85 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
50
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 4, 2026, 8:47 PM EDT
Completed No phase listed Observational

The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease

NCT01329536
View directory record Official record
Conditions
Alzheimer's Disease, Agitation
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Oct 4, 2026, 8:47 PM EDT
Recruiting Phase 1 Interventional

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NCT06372821
View directory record Official record
Conditions
Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
Interventions
NIO752, Placebo
Drug · Other
Lead sponsor
University College, London
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 4, 2026, 8:47 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Genetics Study

NCT00064870
View directory record Official record
Conditions
Alzheimer Disease, Late Onset Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2031
U.S. locations
1
States / cities
Nationwide, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

NCT02292186
View directory record Official record
Conditions
TTR-mediated Amyloidosis
Interventions
Revusiran (ALN-TTRSC)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

NCT05108922
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease
Interventions
Donanemab, Aducanumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 85 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Fullerton, California • Irvine, California • Sherman Oaks, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

NCT01548430
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TTP4000, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Durham, North Carolina • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 4, 2026, 8:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

NCT01680588
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
7
States / cities
New Haven, Connecticut • Chicago, Illinois • Elk Grove Village, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 4, 2026, 8:47 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 1 Interventional

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

NCT02502253
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
grape seed polyphenolic extract, resveratrol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Not applicable Interventional Results available

Optimizing Care for Patients With Dementia

NCT03442322
View directory record Official record
Conditions
Alzheimer Disease
Interventions
transdisciplinary approach, multidisciplinary approach
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 2 Interventional

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease

NCT01073228
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases, Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Chino, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

NCT05408780
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AC-OLE-01-VA
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 4, 2026, 8:47 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
Interventions
[18F]APN-1607
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733
View directory record Official record
Conditions
Alzheimer Disease
Interventions
E2814
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

NCT03823404
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388 capsule, Placebo capsule
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Costa Mesa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 4, 2026, 8:47 PM EDT
Active, not recruiting Not applicable Interventional

I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals

NCT06099197
View directory record Official record
Conditions
Caregiver Burden, Alzheimer Disease
Interventions
Brain CareNotes, Dementia Guide Expert
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 4 Interventional Results available

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

NCT00948766
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 4, 2026, 8:47 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Remternetug (SC), Matching Placebo (Remternetug)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Not applicable Interventional Results available

Hearing Aid and Individuals With Cognitive Disorders

NCT04049643
View directory record Official record
Conditions
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
Interventions
Audiologist-based fitting, Service-only Fitting, Device-only fitting
Device
Lead sponsor
Yu-Hsiang Wu
Other
Eligibility
55 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

NCT01284387
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ACC-001 (vanutide cridificar)
Biological
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 4, 2026, 8:47 PM EDT
Completed Phase 2 Interventional Results available

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

NCT02423200
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VX-745
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 4, 2026, 8:47 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

NCT07688213
View directory record Official record
Conditions
Dementia, Alzheimer's Type, Alzheimer's Disease
Interventions
SAR448851, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Oakland, California • Naples, Florida • The Villages, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 8:47 PM EDT